A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

Seok Jin Kim, Dok Hyun Yoon, Arnaud Jaccard, +28

The Lancet Oncology

Lymphoid NeoplasiaOncologyRetrospective AnalysisPathologyPrognostic Index +5

Blood Lymphocyte-to-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Zhiming Li, Jia-Jia Huang, Yi Xia, +10

PLoS ONE

Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

Tong-Yu Lin, Xuefeng Huang, Jian Gu, +7

Oncogene

Transcriptional RegulationBreast OncologyGfp–trail Fusion GeneMedicineHtert Promoter +9

Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.

Tong-Yu Lin, Jian Gu, Lidong Zhang, +4

PubMed

Antitumor ActivityToxic EffectsApoptosisImmunologyCell Death +18

Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group

Seok Jin Kim, Hyun Ae Jung, Shih‐Sung Chuang, +17

Journal of Hematology & Oncology

Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma

Xiao-Peng Tian, Wei-Juan Huang, Hui-Qiang Huang, +46

Leukemia

Lymphoid NeoplasiaMedicineImmunologyPathologyMicrorna Signature +11

Diagnostic and Prognostic Value of Circulating miR-221 for Extranodal Natural Killer/T-Cell Lymphoma

Hongqiang Guo, Guoliang Huang, Chengcheng Guo, +2

Disease Markers

ImmunologyPathologyImmunotherapyOncologyProgressive Cancer +16

Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers

Tong-Yu Lin, Lidong Zhang, Jian Gu, +5

Molecular Therapy

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma

Jing‐Hua Wang, Liang Wang, Cheng‐Cheng Liu, +5

Oncotarget

ImmunologyPathologyImmunotherapyHematological MalignancyOncology +16

Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial

Chang Liu, Zhi Peng, Yanqiao Zhang, +29

The Lancet

Gastro-oesophageal Junction CancerEsophageal CancerGastrointestinal OncologyMedicineGastroenterology +8